An observational study in Aortoiliac Occlusive Disease, sponsored by W.L.Gore & Associates. Recruiting at 27 sites in 5 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by W.L.Gore & Associates · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (CERAB) to treat Aortoiliac Occlusive Disease (AIOD).
A minimum of 158 adult subjects will be enrolled at up to a minimum of 20 sites in the U.S. and Europe. Data will be collected retrospectively and found within existing site files at Baseline, Treatment, Discharge, Pre-12-Month Follow-up, 12-Month Follow-Up, Subsequent Follow-Up Visits.
W.L.Gore & Associates is the lead sponsor of 96 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
As described in the background section, patients with aortoiliac occlusive disease are treated with various surgical and endovascular therapies to improve arterial blood flow to the lower extremity. This study will retrospectively evaluate a population of patients that have had covered endovascular reconstruction of the aortic bifurcation (CERAB) with GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
The study has been designed with standard eligibility criteria to evaluate the safety and effectiveness of the VBX Device when used in a CERAB for an aortoiliac occlusive disease patient population.
Considering the nature of aortoiliac occlusive disease, elderly patients (≥ 65 years old) can represent a significant number of patients enrolled in this study. This population can include patients with cognitive disorder or severe dementia.
According to EU regulation, elderly patients are considered vulnerable population. However, considering the retrospective nature of the study design, t
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participation in another drug or device study at the time of the CERAB procedure date that can confound the study endpoints.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient was implanted with the VBX Device in the aortic and common iliac positions during the CERAB procedure.
Device: GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
Treatment of Target Lesions with the VBX Device in the aortic and common iliac positions during the CERAB procedure.
Primary Effectiveness Endpoint: 1-Year Primary patency (hypothesis testing)
Proportion of patients maintaining primary patency at 1 Year
Time frame: 1-Year
Primary Safety Endpoint: 30-day Morbidity (hypothesis testing)
Proportion of patients experiencing any major adverse cardiovascular event (i.e. myocardial infarction, cerebrovascular accident) or event requiring reintervention.
Time frame: 30-Day
Technical Success
Proportion of patients with technical success
Time frame: At index procedure
Mortality
Proportion of patients with all cause death
Time frame: 30-Day
Device Integrity
Proportion of patients achieving Primary Patency
Time frame: 1 year
Primary assisted patency
Proportion of patients achieving Primary Assisted patency
Time frame: 1 year
Secondary patency
Proportion of patients achieving Secondary Patency
Time frame: 1 year
Freedom from Target Lesion Revascularization
Proportion of patients achieving freedom from Target Lesion Revascularization
Time frame: 1 year
Survival
Proportion of patients survival
Time frame: 1 Year
Freedom from Clinically-Driven Target Lesion Revascularization
Proportion of patients achieving freedom from Clinically-Driven Target Revascularization
Time frame: 1 year
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.